Inflammation across universal definition of heart failure stages: the CASABLANCA study. (29th November 2022)

• Record Type: Journal Article
• Authors: Mohebi, Reza; Liu, Yuxi; van Kimmenade, Roland; Gaggin, Hanna K.; Murphy, Sean P.; Januzzi, James L.
• Is Part Of: European journal of heart failure. Volume 25:Number 2(2023)
• Page Start: 152
• Page End: 160
• Publication Date: 2022-11-29
• Subjects: Heart failure -- Inflammation -- Biomarker -- Interleukin -- Angiography; Heart failure -- Periodicals; Heart Failure -- Periodicals; Insuffisance cardiaque -- Périodiques; Heart failure; Periodicals; 616.129005
• DOI: 10.1002/ejhf.2742
• Languages: English
• ISSNs: 1388-9842

Abstract

Abstract: Aim: We sought to investigate the association of inflammatory biomarkers with incident heart failure (HF) events in patients at different stages of HF. Methods and results: Overall, 1231 study participants undergoing diagnostic coronary and/or peripheral angiography were categorized by Universal Definition of HF (UDHF) stage A (at risk), stage B (pre‐HF), and stages C or D (HF, including end‐stage). Twenty‐four inflammatory biomarkers were collected prior to angiography and unsupervised machine learning categorized levels of inflammation into three groups (low, medium, and high). Cox proportional hazard regression was implemented to assess the associations of inflammation level with incident HF hospitalization in each UDHF stage. Using machine learning, study participants were grouped into low ( n = 443), medium ( n = 570) and high inflammation categories ( n = 230). Significantly higher concentrations of natriuretic peptide, troponin, and soluble ST2 were observed among those with high inflammation levels ( p < 0.001). During 3.7 years of follow‐up, 123 (15.1%) HF hospitalizations occurred in stage A/B and 180 (41.8%) HF hospitalizations occurred in stage C/D. In multivariable model considering low inflammation level as a reference, among patients with stage A/B, the hazard ratio (HR) (95% confidence interval [CI]) of incident HF was 2.31 (1.40–3.80) for moderate inflammation level, and 4.16 (2.35–7.37) for high inflammation level. Among patients with stage C/D, the corresponding HR (95% CI) of HF hospitalization was 1.98 (1.28–3.04) for moderate inflammation level, and 2.69 (1.69–4.28) for high inflammation level. Conclusion: Patterns of inflammation severity may have differing prognostic meaning across UDHF stages. Abstract : In this prospective observational cohort of patients who underwent angiographic procedures and followed up for incident heart failure (HF) events, association between inflammation levels and risk varied at different HF stages.